Daniela Maftei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Daniela Maftei has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Roberta Lattanzi
Department of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome, Piazzale Aldo Moro 5, I-00185 Rome, Italy
3 shared publications - Alessandra Calculli
Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
2 shared publications - Antonio Pisani
Department of Brain and Behavioral Sciences, University of Pavia, 27100 Pavia, Italy
2 shared publications - Cinzia Severini
Institute of Biochemistry and Cell Biology, National Research Council (CNR)
2 shared publications - Deborah Di Martino
Department of Brain and Behavioral Sciences, University of Pavia , Pavia
2 shared publications - Francesca Gabanella
National Research Council (CNR), Institute of Biochemistry and Cell Biology (IBBC) , Rome
2 shared publications
Latest Publications
- Open Access
- 14 January 2026
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 49 (4)
The Prokineticin system is downregulated in idiopathic rapid eye movement sleep behavior disorder: evidence from olfactory neurons
Study Objectives: PROK2 is a peptide expressed in the adult brain mediating neuroprotective functions. Previous studies reported an upregulation of prokineticin system in Parkinson’s disease (PD), but evidence in prodromal α-synucleinopathies was lacking. We investigated the expression of prokineticin-2 (PROK2) and its receptors (PKR1 and PKR2), along with oligomeric α-synuclein (oligo α-syn) as a marker of α-synuclein pathology, in olfactory neurons (ONs) from individuals with idiopathic rapid eye movement sleep behavior disorder (iRBD). Methods: Olfactory neurons, obtained by nasal brush from 28 idiopathic rapid eye movement sleep behavior disorder subjects (age: 71.2 ± 7.4 years; males: 89.3%; duration: 4.9 ± 2.5 years) and 28 healthy controls (HCs) (age:67.2 ± 11.5 years; males:64.2%), were analyzed using real-time polymerase-chain-reaction (RT-PCR), immunofluorescence (IF), and western blot (WB). In a subgroup of subjects, results were validated in serum. Results: In the idiopathic rapid eye movement sleep behavior disorder group, prokineticin-2 protein expression was reduced in both ONs (immunofluorescence: F(1,26) = 15.289, p < .001; western blot: F(1,12) = 9.073, p = .011) and serum compared with HCs (western blot: F(1,12) = 4.557, p = .050). Idiopathic rapid eye movement sleep behavior disorder subjects showed lower mRNA expression of prokineticin receptors compared with healthy controls (real-time polymerase-chain-reaction for prokineticin receptor-1: F(1,26) = 16.131, p < .001; real-time polymerase-chain-reaction for prokineticin receptor-2: F(1,39) = 4.946, p = .032). Oligo α-syn accumulation in olfactory neurons was higher in idiopathic rapid eye movement sleep behavior disorder than healthy controls, yet the difference only tended to statistical significance (immunofluorescence: F(1,18) = 3.169, p = .092). Conclusions: In contrast with findings in Parkinson’s disease, we found a downregulation of prokineticin system in idiopathic rapid eye movement sleep behavior disorder. The causes of prokineticin system downregulation in this prodromal stage may be multiple. The absence of clear oligo α-syn accumulation, known trigger of prokineticin-2, may play a role. On the other hand, a lack of activation of this system might act as predisposing factor for the development of idiopathic rapid eye movement sleep behavior disorder and, subsequently, full-blown neurodegeneration.
- 14 January 2026
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 49 (4)
Open AccessThe Prokineticin system is downregulated in idiopathic rapid eye movement sleep behavior disorder: evidence from olfactory neurons
Study Objectives: PROK2 is a peptide expressed in the adult brain mediating neuroprotective functions. Previous studies reported an upregulation of prokineticin system in Parkinson’s disease (PD), but evidence in prodromal α-synucleinopathies was lacking. We investigated the expression of prokineticin-2 (PROK2) and its receptors (PKR1 and PKR2), along with oligomeric α-synuclein (oligo α-syn) as a marker of α-synuclein pathology, in olfactory neurons (ONs) from individuals with idiopathic rapid eye movement sleep behavior disorder (iRBD). Methods: Olfactory neurons, obtained by nasal brush from 28 idiopathic rapid eye movement sleep behavior disorder subjects (age: 71.2 ± 7.4 years; males: 89.3%; duration: 4.9 ± 2.5 years) and 28 healthy controls (HCs) (age:67.2 ± 11.5 years; males:64.2%), were analyzed using real-time polymerase-chain-reaction (RT-PCR), immunofluorescence (IF), and western blot (WB). In a subgroup of subjects, results were validated in serum. Results: In the idiopathic rapid eye movement sleep behavior disorder group, prokineticin-2 protein expression was reduced in both ONs (immunofluorescence: F(1,26) = 15.289, p < .001; western blot: F(1,12) = 9.073, p = .011) and serum compared with HCs (western blot: F(1,12) = 4.557, p = .050). Idiopathic rapid eye movement sleep behavior disorder subjects showed lower mRNA expression of prokineticin receptors compared with healthy controls (real-time polymerase-chain-reaction for prokineticin receptor-1: F(1,26) = 16.131, p < .001; real-time polymerase-chain-reaction for prokineticin receptor-2: F(1,39) = 4.946, p = .032). Oligo α-syn accumulation in olfactory neurons was higher in idiopathic rapid eye movement sleep behavior disorder than healthy controls, yet the difference only tended to statistical significance (immunofluorescence: F(1,18) = 3.169, p = .092). Conclusions: In contrast with findings in Parkinson’s disease, we found a downregulation of prokineticin system in idiopathic rapid eye movement sleep behavior disorder. The causes of prokineticin system downregulation in this prodromal stage may be multiple. The absence of clear oligo α-syn accumulation, known trigger of prokineticin-2, may play a role. On the other hand, a lack of activation of this system might act as predisposing factor for the development of idiopathic rapid eye movement sleep behavior disorder and, subsequently, full-blown neurodegeneration.
- Open Access
The Prokineticin System Is Downregulated in Idiopathic Rapid Eye Movement Sleep Behavior Disorder: Evidence from Olfactory Neurons
Objectives: PROK2 is a peptide expressed in the adult brain mediating neuroprotective functions. Previous studies reported an upregulation of prokineticin system in PD, but evidence in prodromal α-synucleinopathies was lacking. We investigated the expression of prokineticin-2 (PROK2) and its receptors (PKR1 and PKR2), along with oligomeric α-synuclein (oligo α-syn) as a marker of α-synuclein pathology, in olfactory neurons (ONs) from individuals with idiopathic REM sleep behavior disorder (iRBD). Methods: ONs, obtained by nasal brush from 28 iRBD subjects and 28 healthy controls (HCs), were analyzed using real-time polymerase chain reaction (RT-PCR), immunofluorescence (IF), and western blot (WB). In a subgroup of subjects, results were validated in serum samples. Results: In the iRBD group, PROK2 protein expression was reduced in both ONs (IF: F(1,26)=15.289, p<0.001; WB: F(1,12)=9.073, p=0.011) and serum compared with HCs (WB: F(1,12)=4.557, p=0.050). iRBD subjects showed lower mRNA expression of prokineticin receptors compared with HCs (RT-PCR for PKR1: F(1,26)=16.131, p<0.001; RT-PCR for PKR2: F(1,39)=4.946, p=0.032). Oligo α-syn accumulation in ONs was higher in iRBD than HCs, yet the difference only tended to statistical significance (IF: F(1,18)=3.169, p=0.092). Conclusion: In contrast with findings in PD, we found a downregulation of prokineticin system in iRBD. The causes of prokineticin system downregulation in this prodromal stage may be multiple. The absence of a clear oligo α-syn accumulation, known trigger of PROK2, may play a role. On the other hand, a lack of activation of this system might act as predisposing factor for the development of iRBD and, subsequently, full-blown neurodegeneration. Statement of significance: This study reveals a downregulation of the prokineticin system in individuals with Idiopathic Rapid Eye Movement Sleep Behavior Disorder (iRBD), a prodromal stage of Parkinson’s disease (PD). Prokineticin-2 (PROK2) is a peptide expressed in the adult brain mediating neuroprotective functions. In contrast to the upregulation reported in established PD, the downregulation observed in iRBD suggests a failure to activate endogenous neuroprotective mechanisms at the prodromal stage of disease, providing new insight into early processes that may predispose to neurodegeneration. Notably, the prokineticin pathway was investigated in olfactory neurons obtained through a simple, non-invasive nasal brushing, demonstrating that these cells represent an innovative and accessible source of biomarkers for central nervous system disorders.
Open AccessThe Prokineticin System Is Downregulated in Idiopathic Rapid Eye Movement Sleep Behavior Disorder: Evidence from Olfactory Neurons
Objectives: PROK2 is a peptide expressed in the adult brain mediating neuroprotective functions. Previous studies reported an upregulation of prokineticin system in PD, but evidence in prodromal α-synucleinopathies was lacking. We investigated the expression of prokineticin-2 (PROK2) and its receptors (PKR1 and PKR2), along with oligomeric α-synuclein (oligo α-syn) as a marker of α-synuclein pathology, in olfactory neurons (ONs) from individuals with idiopathic REM sleep behavior disorder (iRBD). Methods: ONs, obtained by nasal brush from 28 iRBD subjects and 28 healthy controls (HCs), were analyzed using real-time polymerase chain reaction (RT-PCR), immunofluorescence (IF), and western blot (WB). In a subgroup of subjects, results were validated in serum samples. Results: In the iRBD group, PROK2 protein expression was reduced in both ONs (IF: F(1,26)=15.289, p<0.001; WB: F(1,12)=9.073, p=0.011) and serum compared with HCs (WB: F(1,12)=4.557, p=0.050). iRBD subjects showed lower mRNA expression of prokineticin receptors compared with HCs (RT-PCR for PKR1: F(1,26)=16.131, p<0.001; RT-PCR for PKR2: F(1,39)=4.946, p=0.032). Oligo α-syn accumulation in ONs was higher in iRBD than HCs, yet the difference only tended to statistical significance (IF: F(1,18)=3.169, p=0.092). Conclusion: In contrast with findings in PD, we found a downregulation of prokineticin system in iRBD. The causes of prokineticin system downregulation in this prodromal stage may be multiple. The absence of a clear oligo α-syn accumulation, known trigger of PROK2, may play a role. On the other hand, a lack of activation of this system might act as predisposing factor for the development of iRBD and, subsequently, full-blown neurodegeneration. Statement of significance: This study reveals a downregulation of the prokineticin system in individuals with Idiopathic Rapid Eye Movement Sleep Behavior Disorder (iRBD), a prodromal stage of Parkinson’s disease (PD). Prokineticin-2 (PROK2) is a peptide expressed in the adult brain mediating neuroprotective functions. In contrast to the upregulation reported in established PD, the downregulation observed in iRBD suggests a failure to activate endogenous neuroprotective mechanisms at the prodromal stage of disease, providing new insight into early processes that may predispose to neurodegeneration. Notably, the prokineticin pathway was investigated in olfactory neurons obtained through a simple, non-invasive nasal brushing, demonstrating that these cells represent an innovative and accessible source of biomarkers for central nervous system disorders.
- Open Access
Translating human drug use patterns into rat models: exploring spontaneous interindividual differences via refined drug self-administration procedures
Heroin and cocaine users tailor their dosage and frequency of use, as well as their method of administration, to maximize the drugs’ pleasurable effects and prevent withdrawal symptoms. On the other hand, many preclinical self-administration and choice experiments employ fixed unit doses and mandatory timeouts after doses (known as discrete dimension procedures). These restrictions fail to consider the distinct pharmacokinetic properties of heroin and cocaine, leading to uniform and comparable behaviors (including drug-taking patterns). This uniformity contrasts sharply with the significantly different ways humans use heroin and cocaine, which are characterized by highly individualized drug use behaviors. Here, we introduce a no-timeout procedure that overcomes this limitation (continuous dimension procedure). We analyzed the heroin and cocaine taking- and seeking-patterns and estimated drug-brain levels in the presence or absence of timeout between drug injections. We further assessed how absence of timeout and the availability of drug or social peer (access time to the two rewards) affect drug preference. Removing the timeout had a profound effect on pattern of heroin taking and seeking, promoting the emergence of burst-like drug intake and social withdrawal as revealed by a discrete choice procedure. On the other hand, timeout removal had a lesser impact on cocaine taking and seeking and did not impact social preference. By removing timeout during self-administration and increasing the access time during choice resulted in a self-administration procedure that more closely mimic human heroin intake, offering a platform to identify novel medications.
Open AccessTranslating human drug use patterns into rat models: exploring spontaneous interindividual differences via refined drug self-administration procedures
Heroin and cocaine users tailor their dosage and frequency of use, as well as their method of administration, to maximize the drugs’ pleasurable effects and prevent withdrawal symptoms. On the other hand, many preclinical self-administration and choice experiments employ fixed unit doses and mandatory timeouts after doses (known as discrete dimension procedures). These restrictions fail to consider the distinct pharmacokinetic properties of heroin and cocaine, leading to uniform and comparable behaviors (including drug-taking patterns). This uniformity contrasts sharply with the significantly different ways humans use heroin and cocaine, which are characterized by highly individualized drug use behaviors. Here, we introduce a no-timeout procedure that overcomes this limitation (continuous dimension procedure). We analyzed the heroin and cocaine taking- and seeking-patterns and estimated drug-brain levels in the presence or absence of timeout between drug injections. We further assessed how absence of timeout and the availability of drug or social peer (access time to the two rewards) affect drug preference. Removing the timeout had a profound effect on pattern of heroin taking and seeking, promoting the emergence of burst-like drug intake and social withdrawal as revealed by a discrete choice procedure. On the other hand, timeout removal had a lesser impact on cocaine taking and seeking and did not impact social preference. By removing timeout during self-administration and increasing the access time during choice resulted in a self-administration procedure that more closely mimic human heroin intake, offering a platform to identify novel medications.